Compare CIM & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIM | CDNA |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2007 |
| Metric | CIM | CDNA |
|---|---|---|
| Price | $13.55 | $18.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $15.25 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 969.2K | 577.8K |
| Earning Date | 01-01-0001 | 04-01-2026 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | N/A | ★ 126.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $10.42 | $14.49 |
| Revenue Next Year | $27.67 | $11.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $9.85 | $10.96 |
| 52 Week High | $14.88 | $22.95 |
| Indicator | CIM | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 48.05 |
| Support Level | $13.43 | $18.81 |
| Resistance Level | $14.18 | $20.11 |
| Average True Range (ATR) | 0.36 | 1.08 |
| MACD | 0.12 | -0.07 |
| Stochastic Oscillator | 70.41 | 39.56 |
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.